REPORTING GUIDELINE

Recommended parameters for pathology reporting of gastroentero-pancreatic neuroendocrine tumours (GEP-NETs)

The College of Pathologists, Academy of Medicine Malaysia, launched the recommended parameters for pathology reporting of gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) on 22 May 2013 during its 12th Annual Scientific Meeting in conjunction with the International Conference on Medical and Health Sciences (ICMHS) 2013 at the Renaissance Hotel in Kota Bahru, Kelantan, Malaysia. The guidelines were developed with the NET Alliance Interest Group of Malaysia and supported by an educational grant from Novartis Corporation (Malaysia) Sdn Bhd.

The recommended WHO classification and reporting format are reproduced below.

**WHO Classification of Neuroendocrine Neoplasm of the Gastroentero-Pancreatic system (GEP-NETs)**

<table>
<thead>
<tr>
<th>WHO 1980</th>
<th>WHO 2000</th>
<th>WHO 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Carcinoid</td>
<td>1. Well-differentiated endocrine tumour (WDET)</td>
<td>1. Neuroendocrine tumor Grade 1 (carcinoid)</td>
</tr>
<tr>
<td></td>
<td>2. Well-differentiated endocrine carcinoma (WDEC)*</td>
<td>2. Neuroendocrine tumor Grade 2</td>
</tr>
<tr>
<td></td>
<td>3. Poorly differentiated endocrine carcinoma/small-cell carcinoma (PDEC)</td>
<td>3. Neuroendocrine carcinoma Grade 3 large-cell or small-cell type</td>
</tr>
<tr>
<td>III. Mixed forms carcinoid-adenocarcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IV. Pseudotumour lesions</td>
<td>5. Tumour-like lesions (TLL)</td>
<td>5. Hyperplastic and preneoplastic lesions</td>
</tr>
</tbody>
</table>

* If the Ki67 index exceeds 20%, the NET may be labeled G3.

Recommended Parameters for Gastroentero-Pancreatic Neuroendocrine Tumours (GEP-NETs) Pathology Report

An adequate pathology report for GEP-NET must have the following minimum parameters:

- **Organ**: 
- **Procedure**: 

- **Size**: ___________ cm
- **Lymphatic / venous / perineural invasion**
- **Extent of invasion**: 
- **Resection margin**: 
- **IHC**: Chromogranin A (positive/negative) and Synaptophysin (positive/negative)
- **Mitoses (<2 / 2-20 / >20)/10 HPF**
- **% Ki67 (≤2 / 3-20 / >20)** State the percentage: ___%

**Diagnosis**:
- [ ] Neuroendocrine tumor, well differentiated, Grade 1
- [ ] Neuroendocrine tumor, well differentiated, Grade 2
- [ ] Neuroendocrine carcinoma, poorly differentiated, Grade 3
  (Small cell / Large cell NEC)

Launch of the GEP-NETs reporting parameters.

*Left to right: Prof. LM Looi, Dr Arni Talib and Prof. SK Cheong.*